Abstract: Enantiomers of butanediol diglycidyl ether (BDDE) are present in an enantiomerically enriched enantioenriched mixture of BDDE stereisomers or in an enantiomerically pure BDDE. Enantiomerically enriched or pure BDDE is useful as a cross-linking agent, such as in the preparation of a cross-linked hyaluronic acid product.
Type:
Grant
Filed:
August 28, 2015
Date of Patent:
March 6, 2018
Assignee:
GALDERMA S.A.
Inventors:
Jean-Guy Boiteau, Lars Nord, Thibaut Gerfaud
Abstract: The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.
Type:
Grant
Filed:
May 11, 2017
Date of Patent:
January 9, 2018
Assignee:
Galderma S.A.
Inventors:
Yin-Ku Lin, Isabelle Cardinaud, Philippe Andres, Laurent Chantalat, Jean-Thomas Pierson, Antoine Bily, Loïc Le Bronec
Abstract: A graft copolymer comprising: a core polymer comprising a crosslinked or non-crosslinked polysaccharide, a plurality of primary graft polymers covalently grafted to the core polymer, a plurality of secondary graft polymers covalently grafted to each primary graft polymer, an injectable dermal aesthetic formulation comprising such a graft copolymer and a method of preparing such a graft copolymer.
Abstract: A hydrogel product is comprising a chondroitin, molecule selected from the group consisting of chondroitin and chondroitin sulfate as the swellable polymer, wherein the chondroitin molecule is cross-linked into a network via its carboxyl groups. The hydrogel product can be prepared by a process comprising the steps of (a) providing chondroitin molecules; (b) activating the carboxyl groups on the chondroitin molecules with a triazine-based coupling reagent to form an activated, cross-linked chondroitin; and (c) cross-linking the activated chondroitin molecules via their carboxyl groups using a cross-linking agent. The hydrogel product is useful for treatment of soft tissue disorders.
Abstract: A pharmaceutical or cosmetic composition comprising an Indigo Naturalis or Indigo-producing plant extract for treating atopic dermatitis and any form of eczema, and a method of treating atopic dermatitis comprising administering a therapeutically effective amount of an Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
December 5, 2017
Assignee:
Galderma S.A.
Inventors:
Philippe Andres, Laurent Chantalat, Yin-Ku Lin
Abstract: Enantiomers of butanediol diglycidyl ether (BDDE) are present in an enantiomerically enriched enantioenriched mixture of BDDE stereisomers or in an enantiomerically pure BDDE. Enantiomerically enriched or pure BDDE is useful as a cross-linking agent, such as in the preparation of a cross-linked hyaluronic acid product.
Type:
Application
Filed:
August 28, 2015
Publication date:
October 12, 2017
Applicant:
GALDERMA S.A.
Inventors:
Jean-Guy BOITEAU, Lars NORD, Thibaut GERFAUD
Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
Type:
Grant
Filed:
July 8, 2014
Date of Patent:
October 10, 2017
Assignee:
Galderma S.A.
Inventors:
Jean Jacovella, Jean-Paul Chappuis, Alexandre Kaoukhov, Michael Graeber, Laurence Salin, Michel Poncet, Philippe Briantais
Abstract: A hydrogel product including a cross-linked polymer mixture of dextran cross-linked to hyaluronic acid, and one or more cyclodextrin molecules. The one or more cyclodextrin molecules are grafted onto the cross-linked polymer mixture, e.g. by amide bonds. The dextran may be cross-linked to the hyaluronic acid by ether bonds. The one or more cyclodextrin molecules may be grafted onto the cross-linked hyaluronic acid by amide bonds.
Abstract: A hydrogel product including one or more cyclodextrin molecules grafted to hyaluronic acid and dextran, wherein the cyclodextrin-grafted hyaluronic acid is cross-linked to the dextran. The one or more cyclodextrin molecules are grafted, e.g. by amide bonds, to the hyaluronic acid prior to the cross-linking with dextran. The cyclodextrin-grafted hyaluronic acid may be cross-linked to the dextran by ether bonds.
Abstract: A method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by an insect or arthropod sting or bite, or a skin contact with a noxious weed or plant is disclosed. The method includes topically applying a dermatological composition containing an avermectin compound to an affected area immediately after said sting or bite, or said skin contact occurs. The method further includes moistening the affected area first prior to application of the dermatological composition.
Abstract: A method of treating hand-foot syndrome (palmar-plantar erythrodysesthesia) and symptoms associated therewith in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves topically administering a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the affected areas of skin or to the hands and feet.
Abstract: Pharmaceutical/dermatological emulsions containing at least one avermectin compound, notably ivermectin, include at least one fatty phase and at least one aqueous phase, the at least one avermectin compound being solubilized in the fatty phase, which emulsions are useful for the treatment of a variety of dermatological conditions/afflictions, in particular rosacea.
Abstract: A pharmaceutical composition is described that includes a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of atopic dermatitis.
Type:
Application
Filed:
November 28, 2014
Publication date:
January 5, 2017
Applicant:
Galderma S.A.
Inventors:
Feriel Hacini-Rachinel, Emmanuel VIAL, André Jomard
Abstract: Efficient cross-linking of hyaluronic acid (HA) is provided by a manufacturing process. In the process, HA is activated by an initial cross-linking in an aqueous solution. Unreacted cross-linking agent is removed from the activated HA. Cross-linking of the activated HA is finalized, without addition of any additional cross-linking agent, in a suspension of a liquid precipitating medium and the activated HA in precipitated form. The resulting cross-linked HA products exhibit high effective cross-linker ratio and other favorable properties, making the products useful as implants and in medical and cosmetic surgery.
Abstract: A method for lubricating an injection needle when used multiple times at a single occasion to penetrate a support, the method including the steps of: a) depositing a layer of a lubricating composition on the support; b) penetrating multiple times the layer of the lubricating composition deposited in step a) with the injection needle, thereby providing a lubricated injection needle having a deposited layer of the lubricating composition thereon.
Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
Type:
Grant
Filed:
May 22, 2014
Date of Patent:
October 4, 2016
Assignee:
GALDERMA S.A.
Inventors:
Alexandre Kaoukhov, Christophe Villard, Philippe Bouissou
Abstract: The present invention relates to a combination of botulinum toxin and hyaluronic acid for use in the radiation treatment of cancer. The present invention also relates to a method for treating prostate cancer in a human patient, whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved and the rectum is protected from a subsequent radiation treatment step. Furthermore, the present invention relates to one or more compounds selected from botulinum toxin, hyaluronic acid and a combination of botulinum toxin and hyaluronic acid for use in the treatment of prostate cancer in a human patient by a method whereby one or more tumours in the prostate are shrunk, inhibited and/or dissolved and the rectum is protected from a subsequent radiation treatment step.
Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group including the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.
Abstract: A method for manufacturing a shaped cross-linked hyaluronic acid product, the method including the step of subjecting a non-cross-linked precipitated hyaluronic acid substrate in a desired shape to a single cross-linking reaction in a liquid medium having a pH of 11.5 or higher and including one or more polyfunctional cross-linking agent(s) and an amount of one or more organic solvent(s) giving precipitating conditions for hyaluronic acid, under suitable conditions to obtain a precipitated, shaped cross-linked hyaluronic acid product having a degree of modification of 1-40 cross-linking agent units per 1000 disaccharide units.
Type:
Application
Filed:
June 28, 2013
Publication date:
May 26, 2016
Applicant:
GALDERMA S.A.
Inventors:
Morgan KARLSSON, Anne HELANDER KENNE, Åke ÖHRLUND
Abstract: The present invention relates to a hyaluronic acid composition comprising a hyaluronic acid and one or more cyclodextrin molecules covalently bound to said hyaluronic acid via a bi- or polyfunctional crosslinking agent, wherein the covalent bonds between said hyaluronic acid and said crosslinking agent and between said crosslinking agent and said cyclodextrin molecules are ether bonds. The present invention relates to medical and cosmetic (non-medical) uses of such compositions further comprising a pharmaceutical or medical agent and to a method of preparing a slow release formulation.